Marrow Therapeutics announced $173 million in combined funding: a $53 million Series A co-led by Scion Life Sciences and venBio, followed by a $120 million Series B led by OrbiMed. The funding will advance MAR-101, a preclinical candidate for sickle cell disease and beta thalassemia. It links an antibody that targets transferrin receptors to an siRNA payload intended to reduce BCL11A in bone-marrow cells, potentially restoring fetal hemoglobin production. Marrow hopes an injected treatment could avoid some burdens of current gene therapies, which can require stem-cell collection, chemotherapy conditioning and transplantation. The comparison with one-time CRISPR therapy is a development goal—not evidence that MAR-101 is as effective or durable. MAR-101 is still in IND-enabling studies; the company has not disclosed a clinical-trial start date. It has not yet shown human safety or efficacy, so the approach remains unproven. Sources: Sickle Cell Drug: Marrow Raises $173 Millio...
- Get link
- X
- Other Apps